| DIRECT COMPETITOR COMPARISON | |
| CERS | GPRO | HAE | PLL | Industry | | Market Cap: | 73.53M | 2.06B | 1.39B | 3.76B | 100.26M | | Employees: | 107 | 991 | 2,016 | 10,200 | 65 | | Qtrly Rev Growth (yoy): | 24.00% | 1.30% | 7.60% | -9.90% | 19.70% | | Revenue (ttm): | 16.13M | 468.57M | 619.00M | 2.33B | 14.05M | | Gross Margin (ttm): | 26.74% | 70.09% | 52.40% | 47.26% | 65.67% | | EBITDA (ttm): | -24.46M | 157.39M | 141.99M | 419.08M | -12.30M | | Oper Margins (ttm): | -156.37% | 26.02% | 16.63% | 14.15% | -137.11% | | Net Income (ttm): | -25.76M | 88.90M | 66.28M | 195.62M | N/A | | EPS (ttm): | -0.776 | 1.706 | 2.530 | 1.636 | -0.32 | | P/E (ttm): | N/A | 24.61 | 21.38 | 19.64 | 16.37 | | PEG (5 yr expected): | N/A | 1.55 | 1.27 | 1.67 | 1.31 | | P/S (ttm): | 4.68 | 4.43 | 2.25 | 1.64 | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | HAE | | Advocate Renews Deal with Masimo
Fri 12:45pm -
Zacks.com | | • | GPRO | | FDA Nod for Gen-Probe Assay
Wed, Nov 25 -
Zacks.com | | • | GPRO | | Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Tue, Nov 24 -
PR Newswire | | • | PLL | | Pall Corporation Establishes New European Headquarters
Tue, Nov 24 -
Business Wire | | • | PLL | | PALL CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Officer
Mon, Nov 23 -
EDGAR Online | | • | PLL | | Set For Strength to Close 2009
Wed, Nov 18 -
Indie Research | | • | PLL | | Pall 1Q sales hurt by shaky economy
Wed, Nov 18 -
AP | | • | PLL | | UPDATE - Pall Corp sales down 5.4 percent in quarter
Wed, Nov 18 -
at Reuters | | • | GPRO | | Trading Review for Cerus Corp. Issued by Beacon Equity
Wed, Nov 18 -
GlobeNewswire | | • | HAE | | Coverage initiated on Haemonetics by Morgan Keegan
Wed, Nov 18 -
Briefing.com | | • | HAE | | 4-Star Stocks on the Upswing
Tue, Nov 17 -
at Motley Fool | | • | GPRO | | Roche says FDA grants approval for swine flu test
Mon, Nov 16 -
AP | | • | GPRO | | Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
Mon, Nov 16 -
PR Newswire | | • | HAE | | CFN Enters Agreement with Masimo
Fri, Nov 13 -
Zacks.com | | • | GPRO | | GEN PROBE INC Financials
Wed, Nov 11 -
EDGAR Online Financials | | • | HAE | | HAEMONETICS CORP Financials
Tue, Nov 10 -
EDGAR Online Financials | | • | HAE | | Masimo Beats Zacks Estimate
Mon, Nov 9 -
Zacks.com | | • | HAE | | Haemonetics: Cutting-Edge Innovation
Mon, Nov 9 -
at TheStreet.com | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
